Use of pre-s protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infectionClin Vaccine Immunol (2012)
AbstractA hepatitis B virus (HBV) vaccine has been developed using a new adjuvant and HBV surface antigens produced from a CHO cell line. The puriﬁed HBV surface antigens are composed of L protein, M protein, and S protein in a mixture of 20- and 40-nm diameter particles and ﬁlamentous forms. This HBV surface antigen, formulated with L-pampo, a proprietary adjuvant, induced 10 times more antibody than the same antigen with alum and was capable of inducing strong immune responses in three different HBV transgenic mice. In spite of the presence of a large amount of HBV antigen in the blood, no antibody against HBV surface antigen was normally detected in these transgenic mice. After immunization, the HBV antigen was also cleared from the blood.
- hepatitis B,
- virus infection,
Publication DateJanuary 1, 2012
Citation InformationYum, J. S., B. C. Ahn, H. J. Jo, D. Y. Kim, K. H. Kim, H. S. Kim, Y. C. Sung, J. Yoon, J. Morrey, and H. M. Moon. 2012. Use of pre-s protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection. Clin Vaccine Immunol 19:120-127. PMID22155769